StockNews.AI
KAPA
StockNews.AI
113 days

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

1. KAPA will present at ASCO 2025 on KROS 101's effects on T cells. 2. The presentation may enhance investor interest in KAPA's clinical developments.

2m saved
Insight
Article

FAQ

Why Bullish?

KAPA’s participation in ASCO enhances visibility and credibility, historically boosting similar firms' stock prices during major conferences.

How important is it?

Participation at ASCO is significant for clinical stage firms, potentially leading to future partnerships or investments.

Why Long Term?

Results from clinical presentations often influence market perceptions and stock performance many months post-conference.

Related Companies

MGNXPGENBLU
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,” and will be presented on June 2. John Yu, M.D., Kairos C.

Related News